Search Results
Your search for can matches 13754 pages
Showing 2451 - 2500New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Expert Point of View: Javier Cortés, MD, PhD
The invited discussant of the updated APHINITY data was Javier Cortés, MD, PhD, Head of the International Breast Cancer Center in Barcelona. “I think we clearly learned two things from the data. One is that estrogen receptor positivity does not matter in terms of benefit from the addition of...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer
In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
Expert Point of View: Alexey V. Danilov, MD, PhD
According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet medical need, with data from the SCHOLAR-1 study demonstrating a median overall survival of...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
Expert Point of View: Michael Cecchini, MD
The ASCO Post asked Michael Cecchini, MD, Assistant Professor of Medicine and Co-Director of the Colorectal Program in the Center for Gastrointestinal Cancer at Yale School of Medicine and Smilow Cancer Hospital Center, New Haven, to comment on the RATIONALE-306 findings. He said the study...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
Study Reveals Potential Genomic Contributors to the Development of DLBCL
By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
Molecular Map Reveals Insights Into the Genetic Drivers of CLL
A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy, which could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were...
Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL
Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...
Perspective Article Explores Implications of Supreme Court Abortion Ruling on Pregnant Women With Cancer
The repercussions of overturning Roe v Wade—and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother—are potentially catastrophic for a subset of women who face a life-threating diagnosis of pregnancy-associated cancers. In a...
Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Participation
Informed consent forms can be overwhelming for patients—they are written at a level that is too high for many patients, possibly impeding true informed consent, according to a report given by King-Kallimanis et al at the International Association for the Study of Lung Cancer (IASLC) 2022 World...
Models to Assess Impact of Centralization of Specialist Cancer Services in England
In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...
FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab
On August 11, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
Thriving After a Diagnosis of Stage II Anal Cancer
About 7 years ago, I had emergency hernia surgery and soon after began experiencing severe constipation and abdominal bloating. I had started to have minor symptoms leading up to the surgery, but now the pain and exhaustion of trying to have a bowel movement became unbearable. I met with a...
An Oncology Nurse Becomes a Cancer Survivor
In 2016, Theresa Brown, RN, wrote The Shift: One Nurse, Twelve Hours, Four Patients’ Lives, a vivid real-time description of an oncology nurse’s standard 12-hour shift on a hospital cancer ward. It was an excellent book, which was reviewed on these pages and highly recommended for readers of The...
His Grandmother’s Death Inspires a Career in Oncology for Manmeet S. Ahluwalia, MD, MBA
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Manmeet S. Ahluwalia, MD, MBA, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, where his research focuses on the development of new therapies for...
How ASCO and ACCC Aim to Increase Diversity in Clinical Trials and Close the Equity Gap in Cancer Care
Research shows that although 15% of Black individuals and 13% of Hispanic individuals have cancer in the United States, only between 4% and 6% of clinical trial participants are Black and between 3% and 6% are Hispanic.1-3 To improve these statistics, in 2020, ASCO and the Association of Community...
Initiatives by Professional Oncology Organizations Focus on Improving Equitable Cancer Care
At the 2022 Summit on Cancer Health Disparities in Seattle, leaders from five of the leading professional societies in cancer discussed their respective organizations’ current initiatives toward improving cancer health disparities.1 Representatives from ASCO, the American Society for Clinical...
Increased Utilization of SBRT Has Decreased Treatment Disparities for Early-Stage NSCLC
The use of stereotactic body radiotherapy (SBRT) for patients with non–small cell lung cancer (NSCLC) can reduce treatment disparities between White and Black patients, according to research presented by Ganesh et al at the International Association for the Study of Lung Cancer (IASLC) World...
CancerLinQ and Owkin Collaborate to Use Federated Learning on Real-World Oncology Data to Better Understand Lung Cancer Treatment
ASCO’s CancerLinQ and Owkin recently announced a new research collaboration to use artificial intelligence (AI) to analyze real-world oncology data with the aim to understand why some cases of metastatic non–small cell lung cancer (NSCLC) are resistant to first-line immunotherapy. Using data from...
ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
In a collaboration announced on June 4, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the U.N. Sustainable Development Goals and WHO Global Action Plan on Non-Communicable...
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (RCC).1 The guidelines are subdivided into six main sections: diagnosis, the role of cytoreductive nephrectomy, first-line systemic treatment, second- or later-line systemic...
ASCO Endorses New ASTRO Guideline on the Use of Radiation Treatment of Metastatic Brain Cancer
ASCO has endorsed the recommendations put forth in a new guideline, developed by the American Society for Radiation Oncology (ASTRO), on the use of radiation therapy for the management of brain metastases.1,2 Although ASTRO—in conjunction with ASCO and the Society for Neuro-Oncology (SNO)—recently...
An Early Encounter With Cancer Sets a Path to a Career in Oncology Research
To shed some light on the importance of caring for the whole patient and his or her caregiver, as well as the role of cellular aging and oncogenesis, The ASCO Post recently spoke with Kaumudi Bhawe, PhD, a clinical scientist with Cancer Commons in Mountain View, California. Dr. Bhawe has more than ...
Cancer Knows No Borders
This is a critical time for cancer research and cancer care across the world, and the cancer community has clearly highlighted the need for greater and more equitable international collaboration. Addressing the global cancer challenge is a significant undertaking, and it has become more urgent as ...
5-Year Outcomes With Laparoscopic vs Open Distal Gastrectomy in Locally Advanced Gastric Cancer
In the 5-year follow-up of the Korean KLASS-02 trial reported in JAMA Surgery, Son et al found similar 5-year overall survival and relapse-free survival among patients with R0 resection using laparoscopic vs open distal gastrectomy in patients with locally advanced gastric cancer. Late...
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu), an intravenous infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy targeted to patients with the...
Genetics May Predict Bladder Cancer Immunotherapy Response
Investigators have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy with immune checkpoint inhibitors. Their findings, published by You et al in the Journal of the National Cancer Institute, implicate DDR1- and...
Research Shows Poor Patient Comprehension of Terms Commonly Found in Electronic Health Information
When the 21st Century Cures Act went into effect in April 2021, health-care organizations began releasing electronic health information to patients immediately. An aim of the act is to reduce barriers to patients’ timely access to electronic health information, and previous research has shown that...
How Smoking Cessation After a Lung Cancer Diagnosis Improves Overall Survival
Despite data showing that cigarette smoking is the number one risk factor for the development of lung cancer,1 and a leading cause of preventable disease, disability, and death in the United States, an estimated 30.8 million American adults continue to smoke cigarettes.2 Globally, the number of...
Immunotherapy for Gastrointestinal Malignancies: Is It Ready for Prime Time?
In less than a decade, immunotherapy has reshaped the treatment landscape of cancer, but some histologies tend to be more responsive to this modality than others. During the Society of Surgical Oncology 2022 International Conference on Surgical Care, Yuman Fong, MD, of the City of Hope Medical...
Media Emphasis on Urinary Symptoms May Delay Diagnosis of Early Prostate Cancer
According to Cancer Research UK, over 52,000 men are diagnosed with prostate cancer each year in the UK, and there are more than 12,000 deaths. Over three-quarters (78%) of men diagnosed with the disease survive for over 10 years, but this proportion has barely changed over the past decade in the...
Fewer People Tried to Quit Smoking During COVID-19 Pandemic, Study Shows
A new study led by researchers at the American Cancer Society (ACS), shows serious smoking cessation activity declined among adults in the United States immediately after the onset of the COVID-19 pandemic and persisted for more than a year. Declines in attempts to quit smoking were largest among...
New Study Shows Options for Older Patients With Liver Cancer
Physicians and researchers from UK HealthCare's Transplant Center and the University of Kentucky Markey Cancer Center conducted a study of patients over age 70 with hepatocellular carcinoma to examine how the outcomes of ablative treatments compare to liver transplants. The findings were published...
Gaps in Representation of Women and Younger Scholars Among Medical Educators
Women make up just 37.7% of all speakers at hematology and medical oncology board review lectures, according to a study published in Blood Advances. The findings call attention to the many barriers people underrepresented in medicine face in obtaining educational opportunities that can be vital to...
Survey Reveals That Most Americans Are Not Concerned About Getting Lung Cancer
A recent survey shows that only 40% of Americans are concerned that they might get lung cancer, and only about one in five have talked to their doctor about their risk for the disease, despite lung cancer being the leading cause of cancer deaths in the United States. The 2022 Lung Health Barometer, ...
